Browse the corpus

©2013 UpToDate ® Print Email Antiretroviral regimens for occupational postexposure prophylaxis of HIV infection* Preferred regimen Tenofovir-emtricitabine 300/200 mg coformulation once daily plus raltegravir 400 mg twice daily Alternative regimens Tenofovir-emtricitabine 300/200 mg coformulation once daily plus atazanavir 300 mg once daily with ritonanvir 100 mg once daily Tenofovir-emtricitabine 300/200 mg coformulation once daily plus darunavir 800 mg once daily with ritonanvir 100 mg once daily taken with food Additional possible regimens Tenofovir-emtricitabine 300/200 mg coformulation once daily plus lopinavir-ritonavir 400/100 mg coformulation twice daily Efavirenz • -tenofovir-emtricitabine 600/300/200 mg coformulation once daily Stavudine 30 mg twice daily  plus either lamivudine 150 mg twice daily or emtricitabine 200 mg once daily, in place of tenfovir-emtricitabine in one of the above regimens, if tenofovir should be avoided (eg in setting of renal insufficiency) These are recommendations of the authors and are consistent with the 2012 United States Department of Health and Human Services guidelines for treatment of HIV-infected adults. * Usual duration of post-exposure prophylaxis (PEP) is 28 days. Doses shown are for adults with normal renal function. Dose adjustment for renal insufficiency may be needed. • Efavirenz is preferably avoided in women of child-bearing potential. Cognitive side effects due to efavirenz may be better tolerated by taking the coformulation at bedtime. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Department of Health and Human Services. 1-239. Available at   file://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf   Accessed 27 November 2012.